JP2009543768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543768A5 JP2009543768A5 JP2009518964A JP2009518964A JP2009543768A5 JP 2009543768 A5 JP2009543768 A5 JP 2009543768A5 JP 2009518964 A JP2009518964 A JP 2009518964A JP 2009518964 A JP2009518964 A JP 2009518964A JP 2009543768 A5 JP2009543768 A5 JP 2009543768A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- formula
- alkoxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 239000011737 fluorine Substances 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 238000002648 combination therapy Methods 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000005441 aurora Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229930013356 epothilone Natural products 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- -1 fluorine) Chemical class 0.000 claims 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 claims 1
- KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- CXBHMSHVCKEEGW-UHFFFAOYSA-N 4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 CXBHMSHVCKEEGW-UHFFFAOYSA-N 0.000 claims 1
- UWANMJIXIZUGCE-UHFFFAOYSA-N 4-[(2,6-difluorobenzoyl)amino]-n-(1-methylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(F)C=CC=C1F UWANMJIXIZUGCE-UHFFFAOYSA-N 0.000 claims 1
- NPPBDFFMJNUJRY-UHFFFAOYSA-N 4-[(2-fluoro-6-methoxybenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound COC1=CC=CC(F)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 NPPBDFFMJNUJRY-UHFFFAOYSA-N 0.000 claims 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 claims 1
- 108091007914 CDKs Proteins 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- BFZKMNSQCNVFGM-UCEYFQQTSA-N Sagopilone Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@H]1C1=CC=C(SC(C)=N2)C2=C1 BFZKMNSQCNVFGM-UCEYFQQTSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 claims 1
- 229930193320 herbimycin Natural products 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 1
- 229960002014 ixabepilone Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229950007460 patupilone Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 claims 1
- 229950007866 tanespimycin Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229950000578 vatalanib Drugs 0.000 claims 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83104306P | 2006-07-14 | 2006-07-14 | |
| PCT/GB2007/002640 WO2008007113A2 (en) | 2006-07-14 | 2007-07-13 | Pharmaceutical combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543768A JP2009543768A (ja) | 2009-12-10 |
| JP2009543768A5 true JP2009543768A5 (enExample) | 2010-09-02 |
Family
ID=38699782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518964A Pending JP2009543768A (ja) | 2006-07-14 | 2007-07-13 | 医薬組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090263398A1 (enExample) |
| EP (1) | EP2049106A2 (enExample) |
| JP (1) | JP2009543768A (enExample) |
| WO (1) | WO2008007113A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| EP1845974A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| PL2307002T3 (pl) * | 2008-06-09 | 2013-05-31 | Cyclacel Ltd | Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| CA2794801C (en) | 2010-04-07 | 2019-01-15 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| PH12013501800A1 (en) | 2011-03-15 | 2013-10-14 | L Livermore Nat Security Llc | Tricyclic gyrase inhibitors |
| PL2696878T3 (pl) | 2011-04-14 | 2020-01-31 | Cyclacel Limited | Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej |
| PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| PT2870157T (pt) | 2012-07-04 | 2017-11-27 | Rhizen Pharmaceuticals S A | Inibidores seletivos de delta pi3k |
| CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
| WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
| MY199242A (en) | 2016-06-01 | 2023-10-22 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| BR112019003722A2 (pt) | 2016-08-23 | 2019-05-28 | Eisai R&D Man Co Ltd | terapias de combinação para o tratamento de carcinoma hepatocelular |
| CN107880029A (zh) * | 2016-09-30 | 2018-04-06 | 南京大学 | 一类含吡唑骨架的吲哚类衍生物抗肿瘤化合物的设计、合成及应用 |
| WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| EP3911317A2 (en) * | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| CN113005086B (zh) * | 2021-02-01 | 2022-10-28 | 中国科学院遗传与发育生物学研究所 | 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02001498A (es) * | 1999-08-12 | 2003-07-21 | Pharmacia & Italia S P A | Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales. |
| PT1432402E (pt) * | 2001-10-03 | 2007-02-28 | Celator Pharmaceuticals Inc | Composições para administração de combinações de fármacos |
| EP2256106B1 (en) * | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| EP1845973B1 (en) * | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP1845974A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
-
2007
- 2007-07-13 EP EP07766218A patent/EP2049106A2/en not_active Withdrawn
- 2007-07-13 WO PCT/GB2007/002640 patent/WO2008007113A2/en not_active Ceased
- 2007-07-13 US US12/373,713 patent/US20090263398A1/en not_active Abandoned
- 2007-07-13 JP JP2009518964A patent/JP2009543768A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528468A5 (enExample) | ||
| KR102599945B1 (ko) | Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 | |
| JP2023116708A (ja) | 癌を治療するためのｋｒａｓ阻害剤の投与 | |
| JP2008528471A5 (enExample) | ||
| ES2300613T3 (es) | Derivados terapeuticos de piperacina utiles para tratar el dolor. | |
| RU2007131101A (ru) | Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований | |
| US20040072760A1 (en) | Synergistic methods and compositions for treating cancer | |
| US20170259081A1 (en) | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase | |
| JP2005533748A (ja) | 増殖性障害および癌を治療、予防、または管理するための併用療法 | |
| JP2004520299A5 (enExample) | ||
| JP2008528469A5 (enExample) | ||
| RU2009115782A (ru) | Фармацевтические композиции, содержащие нилотиниб или его соль | |
| AU2009277179A1 (en) | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase | |
| NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
| KR102764125B1 (ko) | 혈액암 치료를 위한 조합요법 | |
| US11746103B2 (en) | ALK-5 inhibitors and uses thereof | |
| JP7547360B2 (ja) | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 | |
| JP2004514699A (ja) | Ｇａｂａアゴニストおよびソルビトールデヒドロゲナーゼ阻害剤の組合せ | |
| AU2008318854A1 (en) | Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer | |
| EP3479843A1 (en) | Use of nox inhibitors for treatment of cancer | |
| JP6526789B2 (ja) | 組み合わせ療法 | |
| JP2007528849A (ja) | 増殖性疾患の治療のためのＳｒｃキナーゼ阻害剤および化学療法剤の併用 | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| CN105246480A (zh) | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 | |
| CA3216716A1 (en) | Composition comprising an inhibitor of mitochondrial transcription |